Latest Factor VIII Stories
DEERFIELD, Ill., April 16, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc.
WHIPPANY, N.J., March 4, 2015 /PRNewswire/ -- Bayer HealthCare today announced that the U.S.
DEERFIELD, Ill., Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc.
Marketresearchreports.biz has announced the addition of a new research study on the global and China blood product industry titled China Blood Product Industry Report 2014-2017 to its offering.
DUBLIN, January 27, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment SAN FRANCISCO, Dec.
DIEPENBEEK, Belgium, November 25, 2014 /PRNewswire/ -- Treatment for haemophilia A patients developing Factor VIII inhibitors Apitope, the drug discovery
- Three-year findings regarding prophylaxis versus on-demand treatment in adults with hemophilia A WHIPPANY, N.J., Sept.
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug.
LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy
- An armed gangster.